Cbus Balance of payments: Current account deficit widens 92%
Provence Technologies and Neuroptis Biotech have announced the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech鈥檚 drug candidate, ML7, and producing the first GMP batches before the end of 2012.ML7 is a drug candidate for the treatment o air force1 f dry eye syndromes. It is the first of a new therapeutic class and has the potential to provide a targeted and effective therapeutic remedy for the millions of people suffering from dry eye syndrome, Gougerot-Sjogren syndrome and inflammations, especially ones caused by allergies.Provence Technologies and Neuroptis Biotech have already collaborated successfully in developing a synthetic pathway for ML7, manufacturing the first non-GMP batches and devising associated analytic yeezy al methods.The two companies have embarked on the process optimiz adidas yeezys ation phase to facilitate the transfer of the compound an